23363-35-1 , 4’-去甲基表鬼臼毒素-b-D-葡萄糖甙,
Lignan P,
CAS:23363-35-1
C27H30O13 / 562.5
Lignan P, is a metabolite of Etoposide, which is a DNA topoisomerase II inhibitor. Semi-synthetic derivative of podophyllotoxin, related structurally to Teniposide. It is also an Antineoplastic.
Lignan P is a synthetic analogue of the plant lignans. It has been shown to activate both potassium and calcium ion channels, and has been used as a research tool in pharmacology and cell biology. Lignan P is a ligand that binds to receptors on cells, which may be due to its ability to mimic peptides. This drug also inhibits the activity of protein kinase C, but does not bind to antibodies or compete with other ligands for binding sites on cells. Lignan P has high purity and is an inhibitor of phospholipase A2.
Lignan P is a naturally occurring compound found in plants and has been gaining popularity because of its potential therapeutic properties. The compound has been the subject of numerous studies in various fields of research, including medicine, pharmacology, and food science. This paper aims to provide an in-depth analysis of Lignan P, including its definition, background, physical, and chemical properties, synthesis, characterization, analytical methods, biological properties, toxicity and safety in scientific experiments, applications in scientific experiments, current state of research, potential implications in various fields of research and industry, limitations, and future directions.
Definition and Background:
Lignan P is a type of lignan that is found in plants, especially in flaxseeds and sesame seeds. It is a phytochemical that belongs to the group of non-steroidal compounds and does not have any hormonal properties. Lignan P is known for its antioxidant, anti-inflammatory, and anti-cancer properties. The compound has the ability to interact with estrogen receptors, thereby blocking the activity of estrogen and reducing the risk of hormone-sensitive cancers.
Synthesis and Characterization:
Lignan P is synthesized from plant materials that contain Lignan precursors. The most common source for the production of Lignan P is flaxseeds. The process involves extraction of the lignan precursors from flaxseed hulls and followed by further purification. The purified lignan precursors are then converted to Lignan P through a series of chemical reactions involving hydrolysis, reduction, and demethylation. The product is further purified through column chromatography. The compound is characterized using various techniques such as NMR spectroscopy, Mass spectroscopy, and HPLC.
Analytical Methods:
Several methods have been developed for the analysis and quantification of Lignan P. These methods include HPLC, GC-MS, LC-MS, and NMR spectroscopy. HPLC is the most commonly used method for the quantification of Lignan P, and it involves the separation of the compound from other plant constituents using a reverse-phase column. The separation is achieved using a mobile phase of acetonitrile and water mixed with an acid modifier. UV detection is used to quantify the amount of Lignan P.
Biological Properties:
Lignan P exhibits several biological properties that make it an attractive candidate for use in various fields of research. The compound has antioxidant properties that protect against oxidative stress and inflammation. Lignan P has been shown to possess anti-cancer properties through its ability to regulate cell growth, induce apoptosis, and inhibit tumor angiogenesis. Additionally, Lignan P has been found to have cardiovascular benefits by reducing lipid peroxidation and enhancing endothelial function.
Toxicity and Safety in Scientific Experiments:
Lignan P has been considered to be safe for human consumption. Studies have not revealed any significant side effects or toxicity associated with the use of Lignan P in scientific experiments. However, the compound's safety profile in pregnant and lactating women has not yet been established, and caution should be exercised.
Applications in Scientific Experiments:
Lignan P has been used in several scientific experiments in various fields of research. The compound's antioxidant and anti-inflammatory properties make it an attractive candidate for use in the treatment of conditions such as cardiovascular disease, inflammatory bowel disease, and arthritis. Additionally, the anti-cancer properties of Lignan P make it a potential therapeutic agent in the treatment of cancers such as breast, prostate, and colon cancer.
Current State of Research:
Several studies have been conducted on Lignan P, and the compound's potential therapeutic properties have been explored. However, further studies are needed to fully understand the mechanism of action of Lignan P and its potential therapeutic applications.
Potential Implications in Various Fields of Research and Industry:
The potential applications of Lignan P in various fields of research and industry are vast. The compound's therapeutic properties make it a potential candidate for use in the development of new drugs and supplements. Additionally, Lignan P's antioxidant and anti-inflammatory properties make it a potential ingredient in the food and beverage industry.
Limitations and Future Directions:
Despite the potential benefits of Lignan P, there are limitations to its use. One of the significant limitations is the low solubility of the compound in water, which limits its use in some applications. Additionally, the compound's safety profile has not been fully established for pregnant and lactating women. Future directions for research could include exploring the potential of Lignan P in combination with other compounds for synergistic effects. Research on the compound's potential therapeutic properties in different types of cancers and other diseases could also be an avenue for future research.
In conclusion, Lignan P is a promising compound with potential therapeutic properties for a wide range of conditions. The compound's antioxidant, anti-inflammatory, and anti-cancer properties make it an attractive candidate for use in various fields of research and industry. Further studies are needed to fully explore the compound's potential, and caution should be exercised in its use until a full safety profile is established.
CAS Number | 23363-35-1 |
Product Name | Lignan P |
IUPAC Name | (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-5-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one |
Molecular Formula | C27H30O13 |
Molecular Weight | 562.5 g/mol |
InChI | InChI=1S/C27H30O13/c1-34-16-3-10(4-17(35-2)21(16)29)19-11-5-14-15(38-9-37-14)6-12(11)25(13-8-36-26(33)20(13)19)40-27-24(32)23(31)22(30)18(7-28)39-27/h3-6,13,18-20,22-25,27-32H,7-9H2,1-2H3/t13-,18+,19+,20-,22+,23-,24+,25+,27-/m0/s1 |
InChI Key | FOVRGQUEGRCWPD-BRLGUANISA-N |
SMILES | COC1=CC(=CC(=C1O)OC)C2C3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)OC6C(C(C(C(O6)CO)O)O)O |
Synonyms | Lignan P; (5R,5aR,8aR,9S)-9-(β-D-Glucopyranosyloxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-uro[3’,4’:6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one; |
Canonical SMILES | COC1=CC(=CC(=C1O)OC)C2C3C(COC3=O)C(C4=CC5=C(C=C24)OCO5)OC6C(C(C(C(O6)CO)O)O)O |
Isomeric SMILES | COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O |
联系人:邢经理
手机: 18310328607 , 13621067991,13552979007
电话:86+10-61274189
邮箱:chemsynlab@163.com, zhangchao@chemsynlab.com
地址: 北京市大兴区金苑路26号1幢4层411室